Connect your AI

Zymeworks ZYME Operating Cash Flow

Operating Cash Flow at other companies

PfizerPFE

$2.62B+12.0%

AmgenAMGN

$2.19B+57.4%

AnaptysBio, Inc.ANAB

-$25.92M-142%

AbCellera Biologics Inc.ABCL

-$33.52M-190%

Viridian Therapeutics, Inc.VRDN

-$119.65M-29.1%

Stoke Therapeutics, Inc.STOK

-$60.58M-146%

Other financials

Income statement

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

Market cap$1.76B+125%

Enterprise value$1.53B+112%

P/S21.6×+13.2×

Profitability

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Zymeworks's operating cash flow?: Zymeworks (ZYME) reported operating cash flow of -$45.72M in Q1 2026.
How has Zymeworks's operating cash flow changed year-over-year?: Zymeworks's operating cash flow decreased by 1241.9% year-over-year, from -$3.41M to -$45.72M.
What is the long-term trend for Zymeworks's operating cash flow?: Over 2 years (2022 to 2025), Zymeworks's operating cash flow has grown at a -52.1% compound annual growth rate (CAGR), from $144.11M to -$33.01M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.